Elanco Animal Health vs Perrigo
ELAN and PRGO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELAN and PRGO compare
Elanco Animal Health is the larger company, worth 5.3 times as much as Perrigo ($11.5B against $2.2B).
Elanco Animal Health grew revenue faster over the last twelve months (12.0% versus −4.2% for Perrigo).
Elanco Animal Health keeps more of each dollar of sales as profit, with a net margin of −4.0% compared with −41.9% at Perrigo.
Perrigo pays a dividend yielding 5.5%; Elanco Animal Health does not pay one.
Perrigo scores higher on the StockData Score (10 against 9 for Elanco Animal Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELAN | PRGO |
|---|---|---|
| Size and price | ||
| Market cap | $11.5B | $2.2B |
| Share price | $23.06 | $15.78 |
| Change, 1 year | 2.1% | −25.8% |
| Change, 5 years | −32.4% | −66.0% |
| Beta (5Y) | 1.11 | 0.60 |
| Employees | 9,400 | 8,100 |
| StockData Score | ||
| Total score | 9 | 10 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 3 (better) | 0 |
| Performance score | 3 (better) | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/S | 2.3× | 0.5× (better) |
| P/B | 1.7× | 0.9× (better) |
| EV/EBITDA | 28.3× | – |
| P/FCF | 30.4× | 18.4× (better) |
| FCF yield | 3.3% | 5.4% (better) |
| Fair value | $10.92 | $24.02 |
| Margin of safety | −111% | 34.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.0% (better) | −4.2% |
| Revenue growth, 5Y average | 7.6% (better) | 0.79% |
| Net income growth (TTM) | −146% | – |
| EPS growth (TTM) | −149% | – |
| Profitability | ||
| Gross margin | 55.4% (better) | 33.3% |
| Operating margin | – | −37.7% |
| Net margin | −4.0% (better) | −41.9% |
| FCF margin | 7.5% (better) | 2.9% |
| Return on equity | −3.0% (better) | −49.6% |
| Return on invested capital | – | −18.9% |
| Financial health | ||
| Debt / equity | 0.59 (better) | 1.31 |
| Net debt / EBITDA | 6.43 | – |
| Current ratio | 2.05 | 2.32 (better) |
| Altman Z-score | 1.32 (better) | −0.39 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 5.5% |
| Years of dividend growth | – | 11 |
| Dividend growth, 5Y average | – | 5.2% |
| Shareholder yield | 0.00% | 5.5% (better) |
| Ownership | ||
| Held by institutions | 113% | 116% |
| Held by insiders | 1.1% | 0.36% |
| Insider net buying, 12 months | $2.6M (better) | $106K |
| Short interest, % of float | 7.5% | 17.5% |
Go deeper
- ELAN stock overview
- ELAN income statement
- ELAN valuation and score
- PRGO stock overview
- PRGO income statement
- PRGO valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.